Plain-English translation of NCT06607588 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying how HIV can develop resistance to dolutegravir, a common HIV medication used as a first-line treatment. By analyzing blood samples from people taking this medication, they want to understand when and how resistance emerges, so doctors can better support patients and prevent treatment failure.
Some people taking this medication experience virological failure—meaning the virus isn't being controlled as well as expected. By identifying which genetic changes in the virus lead to treatment resistance, doctors hope to catch problems earlier, adjust treatments more effectively, and improve long-term outcomes for people with HIV.
You likely qualify if…
You likely don't qualify if…
Your participation involves a single visit at Chokwé Hospital's clinic. During this visit, healthcare providers will draw one additional blood sample (beyond your routine care) and collect information about your HIV history, current health, and how well you've been following your treatment plan. The blood sample will be analyzed in a laboratory to check for any genetic changes in your virus that might affect how well your medication works.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
Mozambique
Enrollment target
~200 participants
Started
October 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Daniel Podzamczer, PhD
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.